Skin disease is a serious and common problem in Ireland. Skin conditions are the fourth most common reason for GP visits in Ireland and skin cancer is the commonest form of cancer in Ireland.
The prevalence of skin diseases such as skin cancer, leg ulcers, and atopic eczema has increased steadily over the past 20 years. Today, between 25% and 33% of the Irish population suffers from a dermatological condition at any one time. As a result, Java has considerable experience in clinical trials of dermatological disorders.
Through our affiliation with University College Dublin, we have access to highly experienced researchers in the area of dermatology.
Launched in June 2008, with an investment of €18 million, the Charles Institute at University College Dublin is the first academic institute devoted to dermatology in Ireland. The Institute’s vision is to become a world leader in dermatology research and training, which will lead to improved patient care through the discovery of new treatments and therapies.
At the Charles Institute it is hoped that the application of frontier biotechnologies will provide exciting opportunities to develop worthwhile new therapies for the ultimate benefit of the patient. These will include:
- Micro-therapeutics to generate new drugs for clinical research
- Stem cell therapy which focuses on regenerative medicine
- Tissue repair and wound healing
- Tissue engineering which involves the creation of artificial skin
- Nanobiology for the development of nanomaterials for drug and gene delivery
If you are considering a clinical trial on any aspect of Dermatology, why not tap into our expertise in this field?